Daniel is a Charles H. Revson and Human Frontier Science Program (HFSP) postdoctoral fellow. He received both his B.Sc. and Ph.D. from Tel Aviv University, where he developed a pioneering genome editing-based nanomedicine for cancer therapy. His innovative approach attracted global attention for its potential to treat aggressive cancers like glioblastoma and metastatic ovarian cancer.

In January 2021, Daniel joined the Naik lab as a postdoctoral fellow. His postdoctoral research focuses on the interface between microbes and Intestinal Stem cells in the context of homeostatic adaptation and inflammation. His work has been awarded the 2021 Kenneth Rainin Foundation Innovator Award.  

1. Rosenblum D and Naik S. “New dog, old tricks: Developmental programs resurface in inflammation”, Cell Stem Cell (2021), Vol. 28, no.4.

2. Rosenblum D and Naik S. “Epithelial–immune crosstalk in health and disease”, Current Opinion in Genetics & Development, Volume 74, (2022).

3. Subudhi I, Konieczny P, Prystupa A, Castillo RL, Sze-Tu E, Xing Y, Rosenblum D, Reznikov I, Sidhu I, Loomis C, Lu CP, Anandasabapathy N, Suárez-Fariñas M, Gudjonsson JE, Tsirigos A, Scher JU and Naik S. “Metabolic coordination between skin epithelium and type 17 immunity sustains chronic skin inflammation”, Immunity (2024). Vol 57, Issue 7, P1665-1680.E7.

4. Konieczny P, Subudhi I, Prystupa A, Castillo R, Sidhu I, Sze-Tu E, Xing Y, Rosenblum D, Reznikov I and Naik S “LB1026 An IL-17A-HIF1a axis-controlled dysfunctional epithelial state fuels inflammatory skin disease”, Journal of Investigative Dermatology, Vol.144, Issue 8, (2024).

5. Berger S, Seeger F, Yu TY, Aydin M, Yang H, Rosenblum D, Guenin-Macé L, Glassman C, Arguinchona L, Sniezek C, Blackstone A, Carter L, Ravichandran R, Ahlrichs M, Murphy M, Swanson Pultz I, Kang A, Bera AK, Stewart L, Christopher Garcia K, Naik S, Spangler JB, Beigel F, Siebeck M, Gropp R, and Baker D. "Preclinical proof of principle for orally delivered Th17 antagonist miniproteins”, Cell (2024).